Emil D. Kakkis Sells 25,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 25,000 shares of the company’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $42.48, for a total value of $1,062,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,158,985 shares of the company’s stock, valued at $91,713,682.80. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $40.87 on Thursday. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The stock has a market capitalization of $3.78 billion, a PE ratio of -6.45 and a beta of 0.60. The business’s 50 day moving average price is $42.80 and its 200 day moving average price is $48.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Canaccord Genuity Group upped their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler boosted their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Wedbush reiterated a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RARE. Smartleaf Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. Human Investing LLC acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $42,000. True Wealth Design LLC acquired a new position in Ultragenyx Pharmaceutical during the third quarter worth $43,000. Finally, Van ECK Associates Corp lifted its stake in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 273 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.